Pilot study: Absorption and efficacy of multiple hormones delivered in a single cream applied to the mucous membranes of the labia and vagina

Gynecologic and Obstetric Investigation

Volumn 66, Issue 2, 2008, Pages 111-118

  Glaser, Rebecca L ^a   Zava, David T ^b   Wurtzbacher, Doug ^c  

^a Millennium Wellness Center   (United States)

^b ZRT Laboratory   (United States)

^c Medicine Shoppe Pharmacy   (United States)

Author keywords

Absorption; Estradiol; Estriol; Gonadal steroid hormones; Progesterone; Testosterone; Vaginal creams

Indexed keywords

BASE; ESTRADIOL; ESTRIOL; PRASTERONE; PROGESTERONE; TESTOSTERONE PROPIONATE; UNCLASSIFIED DRUG; VERSABASE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CREAM; DRUG ABSORPTION; DRUG EFFICACY; ESTRADIOL BLOOD LEVEL; ESTRIOL BLOOD LEVEL; FEMALE; HORMONAL THERAPY; HUMAN; MENOPAUSAL SYNDROME; PILOT STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; QUALITY OF LIFE; SALIVA LEVEL; SEX HORMONE DETERMINATION; TESTOSTERONE BLOOD LEVEL; VAGINA; VAGINA MUCOSA;

ADMINISTRATION, INTRAVAGINAL; ADSORPTION; AGED; DEHYDROEPIANDROSTERONE; EMOLLIENTS; ESTRADIOL; ESTRIOL; FEMALE; GONADAL STEROID HORMONES; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; MUCOUS MEMBRANE; PILOT PROJECTS; QUALITY OF LIFE; SALIVA; TESTOSTERONE; VAGINA;

EID: 51149098599     PISSN: 03787346     EISSN: None     Source Type: Journal    
DOI: 10.1159/000128599     Document Type: Article

References (61)

1. Schiff I, Tulchinsky D, Ryan K: Vaginal absorption of estrone and 17β-estradiol. Fertil Steril 1977;28;1063-1066.
2. Schiff I, Wentworth B, Koos B, Ryan K, Tulchinsky D: Effect of estriol administration on the hypogonadal woman. Fertil Steril 1978;30:278-282.
3. Punnonen R, Vilska S, Grönroos M, Rauramo L: The vaginal absorption of oestrogens in post-menopausal women. Maturitas 1980;2:321-326.
4. Heimer G, Englund D: Estriol: absorption after long-term vaginal treatment and gastrointestinal absorption as influenced by a meal. Acta Obstet Gynecol Scand 1984;63:563-567.
5. Heimer G, Englund D: Plasma oestriol following vaginal administration: morning versus evening insertion and influence of food. Maturitas 1986;8:239-243
6. Mattson L, Cullberg G: Vaginal absorption of two estriol preparations: a comparative study in postmenopausal women. Acta Obstet Gynecol Scand 1983;62:393-396.
7. Cedars M, Judd H: Nonoral routes of estrogen administration. Menopause 1987;14:269-298.
8. Carlström K, Pschera H, Lunnell N: Serum levels of oestrogens, progesterone, follicle-stimulating hormone and sex-hormone-binding globulin during simultaneous vaginal administration of 17 beta-oestradiol and progesterone in the pre- and post-menopause. Maturitas 1988;10:307-316.
9. Suh-Burgmann E, Sivret J, Duska L, Carmen M, Seiden M: Long-term administration of intravaginal dehydroepiandrosterone on regression of low-grade cervical dysplasia - a pilot study. Gynecol Obstet Invest 2003;55:25-31.
10. Keller PJ, Riedmann R, Fischer M, Gerber C: Oestrogens, gonadotropins and prolactin after intra-vaginal administration of oestriol in post-menopausal women. Maturitas 1981;3:47-53.
11. Rigg LA, Hermann H, Yen SS: Absorption of estrogens from vaginal creams. N Engl J Med 1978;298:195-197.
12. Rosano G, Webb C, Chierchia S, Morgani G, Gabraele M, Sarrel P, Ziegler D, Collins P: Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women. J Am Col Cardiol 2000;36:2154-2159.
13. Oriba H, Bucks D, Maibach H: Percutaneous absorption of hydrocortisone and testosterone on the vulva and forearm: effect of the menopause and site. Br J Derm 1996;134:229-233.
14. Corbo D, Liu JC, Chien Y: Drug absorption through mucosal membranes: effect of mucosal route and penetrant hydrophilicity. Pharmac Res 1989;6:848-852.
15. Friedrich E, Kalra P: Serum levels of sex hormone in vulvar lichen sclerosus, and the effect of topical testosterone. N Engl J Med 1981;310:488-491.
16. Nahoul K, Dehennin L, Jondet M, Roger M: Profiles of plasma estrogens, progesterone and their metabolites after oral or vaginal administration of estradiol or progesterone. Maturitas 1993;16:185-202.
17. Mandel F, Geola F, Meldrum D, Lu J, Eggena P, Sambhi M, Hershmann J, Judd H: Biological effects of various doses of vaginally administered conjugated equine estrogens in postmenopausal women. J Clin Endo Met 1983;57:133-139.
18. Bottiglione F, Volpe A, Esposito G, Aloysio D: Transvaginal estriol administration in postmenopausal women: a double blind comparative study of two different doses. Maturitas 1995;22:227-232.
19. Schiff I, Tulchinsky D, Ryan K, Kadner S, Levitz M: Plasma estriol and its conjugates following oral and vaginal administration of estriol to postmenopausal women: correlations with gonadotropin levels. Am J Obstet Gynecol 1980;138:1137-1141.
20. Ross D, Cooper A, Pryse-Davies J, Bergeron C, Collins W, Whitehead M: Randomized, double-blind, dose-ranging study of the endometrial effects of a vaginal progesterone gel in estrogen-treated postmenopausal women. Am J Obstet Gynecol 1997;177:937-941.
21. Cicinelli E, Cignarelli M, Sabatelli S, Romano F, Schonauer L, Padovano R, Einer-Jensen N: Plasma concentrations of progesterone are higher in the uterine artery than in the radial artery after vaginal administration of micronized progesterone in an oil-based solution to postmenopausal women. Fertil Steril 1998;69:471-473.
22. Levine H, Watson N, Comparison of the pharmacokinetics of crinone 8% administered vaginally versus prometrium administered orally in postmenopausal women. Fertil Steril 2000;73:516-521.
23. Ware J Jr, Kosinski M, Keller SD: A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996;34:220-233.
24. Gourley GA, Duncan DV: Patient satisfaction and quality of life: humanistic outcomes. Am J Manag Care 1998;4:746-752.
25. Spilker B: Introduction;in Spilker B (ed): Quality of Life and Pharmacoeconomics in Clinical Trials, ed 2. Philadelphia, Lippincott-Raven, 1996, pp 1-10.
26. Testa MA, Simonson DC: Assessment of quality-of-life outcomes. N Engl J Med 1996;334:835-840.
27. Bootman JL, Townsend RJ, McGhan WF: Principles of Pharmacoeconomics, ed 2. Cincinnati, Harvey Whitney Books, 1996.
28. Villanueva B, Casper RF, Yen SC: Intravaginal administration of progesterone: enhanced absorption after estrogen treatment. Fertil Steril 1981;35:433-437.
29. Zeisler E, Bancher-Todesca D, Sator M, Schneider B, Gitsch G: Short-term effects of topical testosterone in vulvar lichen sclerosis. Obstet Gynecol 1997;89:297-299.
30. Vooijs GP, Geurts TBP: Review of the endometrial safety during intravaginal treatment with estriol. Obstet Gynecol 1995;62:101-106.
31. Bergkivist L, Adami H, Persson I, Hoover R, Schairer C: The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 1985;321:293-297.
32. Dew J, Eden J, Beller E, Magarey C, Schwartz P, Crea P, Wren B: A cohort study of hormone replacement therapy given to women previously treated for breast cancer. Climacteric 1998;1:137-142.
33. Dew J, Wren B, Eden J: A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer. Climacteric 2003;6:45-52.
34. Fournier A, Berrino F, Riboli E, Avenel V: Clavel-Chapelon F: Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 2004;114:448-454.
35. Fournier A, Berrino F, Clavel-Chapelon F: Unequal risks for breast cancer associated with different hormone replacement therapies; results from the E3N cohort study. Breast Cancer Res Treat 2008;107:103-111.
36. Lyytinen H, Pukkala E, Ylikorkala O: Breast cancer risk in postmenopausal women using estrogen-only therapy. Obstet Gynecol 2006;108:1354-1360.
37. Rosenberg L, Magnusson C, Lindstrom E, Wedren S, Hall P, Dickman P: Menopausal hormone therapy and other breast cancer risk factors in relation to the risk of different histological subtypes of breast cancer: a case-control study. Breast Cancer Res 2006;8:R11.
38. Blum M: Benefits of vaginal estriol cream combined with clonidine HCl for menopausal syndrome treatment. Clin Exp Obstet Gynecol 1985;12:1-2.
39. Fink RS, Collins W, Papadaki L, O'Reilly B, Ginsburg J: Vaginal oestriol: effective menopausal therapy not associated with endometrial hyperplasia. J Gynaec Endocrinol 1985;1:1-11.
40. Weiderpass E, Baron J, Adami H, Magnusson C, Lindgren A, Bergstrom R, Correia N, Persson I: Low-potency oestrogen and risk of endometrial cancer: a case-control study. Lancet 1999;353:1824-1828.
41. Michaelsson K, Baron J, Farahmand B, Ljunghall S: Use of low potency estrogens does not reduce the risk of hip fractures. Bone 2002;30:613-618.
42. Trevoux R, Van der Velden W, Popovis D: Ovestin vaginal cream and suppositories for the treatment of menopausal vaginal atrophy. Reproduction 1982;6:101-106.
43. Levy T, Yairi Y, Bar-Hava I, Shalev J, Orvieto R, Ben-Rafael Z: Pharmacokinetics of the progesterone-containing vaginal tablet and its use in assisted reproduction. Steroids 2000;65:645-649.
44. Kuhl H: Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric 2005;8(suppl 1):3-63.
45. Ficicioglu C, Gurbuz B, Tasdemir S, Yalti S, Canova H: High local endometrial effect of vaginal progesterone gel. Gynecol Endocrinol 2004;18:240-243.
46. de Lignieres B, Dennerstein L, Backstrom T: Influence of route of administration on progesterone metabolism. Maturitas 1995;21:251-257.
47. Jaaskelainen A, Shaerer E, de Ziegler D: Vaginal progesterone (P) in menopause: long term acceptability of a new therapeutic option for physiological progesterone replacement. Maturitas 1997;27(suppl 1):57.
48. Ando S, De Amicis F, Rago V, Carpino A, Maggiolini M, Panno M, Lanzino M: Breast cancer: from estrogen to androgen receptor. Mol Cell Endocrinol 2002;193:121-128.
49. Ortmann J, Prifti S, Bohlmann M, Rehberger-Schneider S, Strowitzki T, Rabe T: Testosterone and 5-alpha-dihydrotestosterone inhibit in vitro growth of human breast cancer cell lines. Gynecol Endocrinol 2002;16:113-120.
50. Lapointe J, Fournier A, Richard V, Labrie C: Androgens down-regulate bcl-2 proto-oncogene expression in ZR-75-1 human breast cancer cells. Endocrinology 1999;140:1416-1421.
51. Zhou J, Ng S, Adesanya-Famuiya O, Anderson K, Bondy C: Testosterone inhibits estrogen-induced mammary epithelial proliferation and suppresses estrogen receptor expression. FASEB J 2000;14:1725-1730.
52. Dimitrakakis C, Zhou J, Wang J, Belanger A, LaBrie F, Cheng C, Powell D, Bondy C: A physiologic role for testosterone in limiting estrogenic stimulation of the breast. Menopause 2003;10:292-298.
53. Dimitrakakis C, Jones R, Liu A, Bondy C: Breast cancer incidence in postmenopausal women using testosterone in addition to usual hormone therapy. Menopause 2004;11:531-535.
54. Hofling M, Hirschberg Q, Skoog L, Tani E, Hagerstrom T, von Schoultz B: Testosterone inhibits estrogen/progestogen-induced breast cell proliferation in postmenopausal women. Menopause 2007;14:1-8.
55. de Goyer M, Oppers-Tiemissen H, Leysen D, Verheul H, Kloosterboer J: Tibolone is not converted by human aromatase to 7-alpha methyl 17-alpha ethynylestradiol: analyses with sensitive bioassays for estrogens and androgens with LC-MSMS. Steroids 2003;68:235-243.
56. Tamimi R, Hankinson S, Chen W, Rosner B, Colditz G: Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women. Arch Intern Med 2006;166:1483-1488.
57. Million Women Study Collaborators: Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-427.
58. NIH State-of-the-Science Conference Statement on management of menopause-related symptoms. NIH Consens Stat Sci Statements 2005;22:1-38.
59. Reed PJ: Medical outcomes study short form 36: testing and cross-validating a second-order factorial structure for health system employees. Health Serv Res 1998;33:1361-1380.
60. Schneider HPG, Heinemann LAJ, Rosemeier HP, Potthoff P, Behre HM: The Menopause Rating Scale (MRS): comparison with Kupperman Index and Quality of Life Scale SF-36. Climacteric 2000;3:50-58.
61. Dinger J, Zimmermann T, Heinemann LA, Stoehr D: Quality of life and hormone use: new validation results of MRS scale. Health Qual Life Outcomes 2006;4:32.